CLINICALLY PROVEN | EFFICACY EXPECTED FROM A PGA*
A European noninferiority study (N=353) comparing preservative-free latanoprost (n=213) to BAK-preserved latanoprost (n=189) showed comparable mean IOP in patients at day 15, day 42, and day 84.1
XALATAN is a registered trademark of Pfizer PFE Holdings 4 LLC, a Viatris Company.
In the US Phase III TRIAL
AT DAY 84,
73%
of patients using IYUZEH™ (latanoprost ophthalmic solution) 0.005% had IOP <18 mmHg.2
This was a prospective, randomized, multicenter, observer-masked, noninferiority phase III trial (N=335) conducted at 31 sites across the US to evaluate the noninferiority of IYUZEH compared to XALATAN® in patients with open-angle glaucoma or ocular hypertension.2
FURTHER IOP REDUCTION FOLLOWING SWITCH TO PRESERVATIVE-FREE LATANOPROST3
In a prospective, longitudinal, open-label, multicenter study conducted at eight glaucoma centers in Poland, 140 patients whose IOP had been well-controlled on preserved latanoprost for an average of 5.8 years were switched to preservative-free latanoprost.3
PGA=prostaglandin f2α analogue; IOP=intraocular pressure.
*According to primary open-angle glaucoma Preferred Practice Pattern® Guidelines, the expected IOP reduction with the prostaglandin class of drugs is 25% to 33%.4
♠The results of this study should be considered in the context of the limitations of this type of evidence. While these findings provide insights into the real-world performance of IYUZEH, they may not be directly comparable to results from clinical trials.
Eileen used a generic latanoprost for a few years but grew concerned about products with unnecessary additives. After researching ophthalmic treatment options, she became interested in switching to a benzalkonium chloride (BAK)—free option.
Eileen heard about IYUZEH – the first and only preservative-free latanoprost. With the help of her eye care professional, she switched and is very satisfied with her treatment.
†Patient portrayal. Not an actual patient.
